Ensysce Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on June 17, 2022, reporting events occurring on June 16 and June 17, 2022. Ensysce Biosciences, Inc. (ENSC) is a Delaware corporation with its principal executive offices in La Jolla, California. The company's common stock and warrants trade on the Nasdaq Capital Market and OTC Pink Open Market, respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it notes that the company currently does not meet the Nasdaq continued listing standard for minimum stockholders' equity of at least $2.5 million.
Material Changes and Listing Notices
- Minimum Value of Listed Securities (MVLS) Deficiency: On June 16, 2022, Nasdaq notified the company that its MVLS had been below the required $35 million for 30 consecutive business days. The company has until December 13, 2022, to regain compliance by maintaining an MVLS of $35 million or more for 10 consecutive business days.
- Minimum Bid Price Deficiency: On June 17, 2022, Nasdaq notified the company that its common stock bid price had closed below $1.00 per share for 30 consecutive business days. The company has until December 14, 2022, to regain compliance by maintaining a closing bid price of $1.00 or more for 10 consecutive business days.
- Current Status: These notices have no immediate effect on the listing, and the stock continues to trade on Nasdaq. Failure to comply by the respective deadlines may result in delisting notices, subject to appeal.
Guidance, Outlook, and Management Commentary
On June 17, 2022, the company updated its timeline for the Bioequivalence (BE) trial data of its TAAP opioid, PF614. The data is now expected to be available prior to the end of July 2022. Management stated it intends to actively monitor MVLS and bid price metrics and evaluate options to resolve deficiencies, though there is no assurance of regaining compliance.
Investor Verification Checklist
- Verify the current Minimum Value of Listed Securities (MVLS) and whether it has reached the $35 million threshold.
- Monitor the daily closing bid price to ensure it sustains above $1.00 per share for the required 10-day period.
- Confirm the anticipated release date of the PF614 Bioequivalence trial data before the end of July 2022.
- Review upcoming filings for any announcements regarding reverse stock splits or other capital actions intended to address listing deficiencies.
- Check for any subsequent Nasdaq communications regarding the extension or shortening of the compliance periods.